

# Phase II trial: ETH47-201

<b>Submission date</b> 23/05/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 03/06/2025	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 03/06/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Onn Min Kon

### Contact details

Imperial College Healthcare NHS Trust  
South Wharf Road  
London  
United Kingdom  
W2 1NY  
+44 (0)203 312 1344  
onn.kon@nhs.net

### Type(s)

Scientific

### Contact name

Dr Michael Edwards

### Contact details

2 Royal College Street  
London  
United Kingdom

NW1 0NH  
+44 (0)20 7554 5855  
info@virtus-rr.com

### **Type(s)**

Public

### **Contact name**

Ms Tika Endeladze

### **Contact details**

2 Royal College Street  
London  
United Kingdom  
NW1 0NH  
+44 (0)20 7554 5855  
info@virtus-rr.com

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **Integrated Research Application System (IRAS)**

1011224

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

ETH47-201

## **Study information**

### **Scientific Title**

Phase II trial: ETH47-201

### **Study objectives**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 14/02/2025, Wales 3 REC (Wales Research Ethics Committee 3, Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941107; Wales.REC3@wales.nhs.uk), ref: 25/WA/0013

**Study design**

Phase II double-blind randomized placebo-controlled study in 50 volunteers with asthma

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Interventions**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Intervention Type**

Drug

**Phase**

Phase II

**Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Completion date**

12/05/2026

**Eligibility****Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

**Date of first enrolment**

09/06/2025

**Date of final enrolment**

12/05/2026

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Imperial College Respiratory Research Unit**

Imperial College Healthcare NHS Trust

Mint Wing

South Wharf Road

St Mary's Hospital

London

United Kingdom

W2 1NY

**Sponsor information****Organisation**

Ethris GmbH

# Funder(s)

## Funder type

Industry

## Funder Name

Ethris GmbH

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials

## IPD sharing plan summary

Not expected to be made available

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes